Here's my response from Traxxec. It looks like they are sending out a corporate response to cover all enquiries which is the usual pracice with Corps - a briefing pack if you like.
Dear XXXXXXXX,
Thank you for your enquiry; all of the information you requested (and more)is contained in a reply I sent to another enquirer. Please find my reply to him below:
Reply per pro Mrs Amy Scopes
Dear Mr XXXXXXXX,
I am pleased you have found the website interesting but I am disappointed that you have shown no direct interest in the opportunity the business model offers you with your investment.
On January 6th 2008 you e-mailed the enquiry desk, without any declaration or disclosure of interest, other than to say that you were intrigued that Traxxec had been “acquired” by Medify Solutions. In good faith, a reply was sent to you explaining that Traxxec had not been acquired by Medify Solutions and I confirm that there is no commercial connection with any company, other than Rexam by a patent exclusive license agreement, including Medify or any other companies. Understandably I am not able to comment on any historical company or procedure that this company was not part of.
Traxxec was acquired by CRVR which is the parent. Traxxec is, following re-structure and re-organisation the sole operational activity of CRVR and the existing management team and board were replaced with immediate effect by the Board of Traxxec at the closing of the Medify Business.
Your e-mail sent on 4th March 2008 to which I am replying contains, fundamentally, your opinion of the “protocols” that the company should have followed and, whilst the company is pleased to consider opinion for the betterment of its performance, it is only opinion.
Website To enable a better understanding of the business model the website was specifically written to inform shareholders and prospective investors and to invite enquiry. To that end I think we have achieved our goal.
Your assertion that full bios of all principals of any publicly traded company are included on their web-site is completely without foundation. In our parochial situation there is no mention of the Managing Director of Rexam Pharma who was the executive officer who signed the license agreement nor is there any mention of the legal team who were principal in preparing the agreement. In the case of our development partners, neither of their sites include bios of the managing director and the vice president who signed the confidentiality agreements or letters of intent to commit their employer to work jointly on a development programme and neither do they include bios of the management team or advocates or members of the board, executive or advisory. However, Mrs Scopes will be considering whether to include a short bio in the website.
Founders To my knowledge, there is no mention on the website of a founder. Throughout there is mention of the founders (plural) and this term of reference, as is commonly found with Research and Development companies, is used in its generic definition of those who bring in to being, or establish, to build or establish the foundation of – def. Collins Concise. As such, in the development of the product and in arriving at the agreement with Rexam considerable expertise has been employed. This ranges from test/evaluation facilities such as TWI (www.twi.co.uk) – you will note there are no bios of the principals of the organisation – manufacturing facilities, small, private development companies and consultancies such as Climate Group Holdings, Clinical Mangement Telemetrics and the Centre for Healthcare Innovation and Design. One such consultancy has been retained to fulfil the license agreement Article 8 – TECHNICAL ASSISTANCE. As has been mentioned in response to other enquirers, most work carried out in R and D is covered by a Confidentiality Agreement and with Rexam it is Article 9. – CONFIDENTIALITY that states, amongst other specifics, the parties undertake to maintain confidentiality concerning all information relating to this agreement that is not already in the public domain. Of the highest importance, the Patent and license agreement is owned by Traxxec, and hence Columbia River Resources Inc., and covers all the intellectual property pertinent to the finished RFID technology that is supplied to Rexam i.e. – CRVR/Traxxec own the patent on the completed product that uses the combined technologies.
Confidentiality All development work for the Radio Frequency Enabled Bottle has been carried out under such confidentiality. By way of explanation, the drug you buy from a major pharmaceutical company has possibly never been on a facility of that company during its cradle to grave history from drug discovery, through the phases of clinical trials, formulation, packing and distribution. The work has been out-sourced and covered by various agreements, including (possibly) in the early stages, payment by future royalty from sales under license. The product we supplied to a pharmaceutical company in the US was supplied under such terms and conditions and confidentiality; the bottle, ordered and specified by the pharma company, was manufactured in Europe, delivered to a US formulation company who packed the drug in to the primary pack where it was delivered to another contract organisation for packing in patient kits for distribution to patients etc etc. I notice from your e-mail address that you are possibly based on the West Coast where there is a focus on bio-tech and research companies, including our client, all working under similar arrangements and the strictest terms of confidentiality.
RFID Generally, the application of this technology is an integration of software, hardware and systems design and each part of the whole is supplied by an expert in its field – the microchip by, say, Philips, the suitable and robust packaging of the chip by Sokymat, readers by Nordic and software by Germane Systems Ltd. Germane Systems Ltd had been retained by the company to provide the technical assistance and support agreed in the license agreement with Rexam – this is a billable item. This is a systems integration company that has worked in auto-id for the last eight years and previously on projects such as the implementation of software and hardware for the X-ray facility at Schiphol airport. The company also provided the Quality Control and Quality Assurance software for the production of the bottles supplied in the US, Eu and to Rexam.
Amy Scopes Amy was born in St. Asaph, North Wales, UK and is 37 years of age, married with three children. She was the ideal candidate for the position of CEO having previously been employed by CGH in a senior management position and having directly implemented a product licensing agreement to supply the National Pharmaceutical Association with an innovative packaging solution for monitored dosage systems for residential and domiciliary use.
She has been employed by this SME since 1998. During the time she was employed by the company she had direct contact with many of the manufacturing sub-contractors and developers as well as with the technology consultancies giving a continuity of relationship with “the founders”.
Pink Sheets We fully agree with your opinion that the “STOP” category is not beneficial to the Company, and believe it is a poor representation of the potential offered by our Company. The process of upgrading to Current Information is one in which, I am informed, we are actively involved. In truth, the Company expects to upgrade to this category only briefly, before moving to OTCQX.
From your comments it appears you have never been involved in this process, so please allow me to explain the procedures we are currently following. These procedures are fully outlined on the Pink Sheets site, www.pinksheets.com. Initially the Issuer, in this case Traxxec parent company Columbia River Resources Inc, must subscribe to OTCIQ. This is the “Back end” of Pink Sheets and allows the issuer to post information to the Pink Sheets page, and to edit company information. The previous incumbents had not even completed this basic step.
We anticipate that we will be subscribed by Monday next week.
After subscribing to OTCIQ the Issuer is then required, if they wish to upgrade their disclosure category, to complete and post disclosure documents. This document is in final draft stage internally, and will be published as soon as possible. Pink Sheets review this document, along with an Attorney letter supporting the disclosure statement, and either approve the upgrade or request further information.
On completion and approval of the upgrade to Pink Sheets Current Information the Company then has the option of paying a further subscription fee and upgrading to OTC QX, the highest tier of Pink Sheets. This decision will be considered at the appropriate time.
I trust this reply in good faith to essentially an unqualified approach is satisfactory and I repeat the offer in my reply to your e-mail in January that, if you wish to disclose your level of interest in this company and require further, appropriate, confidential information please do not hesitate to contact me.
The level of enquiry is extremely high and this pasted document is virtually a corporate template.
Sincerely,
Marie Mear
ENQUIRIES
Tel: 0845 396 8168
This e-mail message (and attachments) may contain information that is confidential to Traxxec Ltd., a company registered in England and Wales. If you are not the intended recipient you cannot use, distribute or copy the message or attachments. In such a case, please notify the sender by return e-mail immediately and erase all copies of the message and attachments.
Traxxec Ltd., Registered in England and Wales under company number 5733762
Registered Office: 138, Hassell Street, Newcastle under Lyme, Staffordshire. ST5 1BB
VAT No. 892 7961 61
